{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-087273","form_type":"8-K","ticker":"NTRA","cik":"0001604821","company_name":"Natera, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.742524+00:00","generated_at":"2026-05-31T10:56:44.268676+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Natera Q2 revenue up 58% to $413.4M, loss narrows to $37.5M, guides higher","bullets":["Revenue $413.4M (+58.1% YoY); product revenue $411.4M (+59.3%); gross margin 58.8% vs 45.2%.","Net loss $37.5M ($0.30 loss per share) vs $110.8M ($0.97) YoY; operating loss $43.9M vs $112.4M.","Processed ~760,300 tests (+23.2%); oncology tests up 50.2% to ~125,400.","Achieved positive cash flow ~$3.3M; FY 2024 revenue guidance raised to $1.49-$1.52B.","Cash and investments $887.1M; outstanding debt $364.0M as of June 30, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-087273","json":"https://secwatch.observer/filing/0001104659-24-087273.json","markdown":"https://secwatch.observer/filing/0001104659-24-087273.md","text":"https://secwatch.observer/filing/0001104659-24-087273.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604821/000110465924087273/0001104659-24-087273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604821/000110465924087273/tm2420614d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:56:44.268676+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}